Statistics from Altmetric.com
Electrophysiology, general cardiology
Flec-SL: short- versus long-term flecainide after AF cardioversion
The goal of antiarrhythmic therapy following cardioversion for atrial fibrillation (AF) is to prevent further recurrences for as long as possible. However, it is known that the atrial action potential normalises after 2–4 weeks of sinus rhythm, suggesting that drugs may not be essential in the long-term. The goal of this study was to investigate whether short-term antiarrhythmic treatment following cardioversion for AF was non-inferior to long-term treatment.
In this prospective, randomised trial, patients at 44 centres in Germany were randomly assigned to either no antiarrhythmic treatment, treatment with 200–300 mg of flecainide per day for 4 weeks, or flecainide treatment for 6 months. The primary endpoint measure was the time to persistent AF or death, the former being assessed in a core laboratory who were masked as to the patient's treatment group.
Overall the primary outcome occurred in 46% of patients receiving short-term treatment versus 39% of patients receiving long-term treatment; the difference between the two groups in the mean percentage of patients who did not have persistent AF was 7.9%, which did not reach the specified non-inferiority margin (p=0.2081). A post-hoc analysis of all patients who had not reached the primary endpoint in the …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.